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Abstract: Providing access to and utilization of medication assisted treatment (MAT) for 
the treatment of opioid abuse and dependence provides an important opportunity to 
improve public health. Access to health services comprising MAT in the community is 
fundamental to achieve broad service coverage. The type and placement of the health 
services comprising MAT and integration  with primary medical care including human 
immunodeficiency virus (HIV) prevention, care and treatment services are  optimal  for 
addressing both substance abuse and co-occurring infectious diseases. As an HIV 
prevention intervention, integrated (same medical record for HIV services and MAT 
services) MAT with HIV prevention, care and treatment programs provides the best “one 
stop shopping” approach for health service utilization. Alternatively, MAT, medical and 
HIV services can be separately managed but co-located to allow convenient utilization of 
primary care, MAT and HIV services. A third approach is coordinated care and treatment, 
where primary care, MAT and HIV services are provided at distinct locations and case 
managers, peer facilitators, or others promote direct service utilization at the various 
locations. Developing a continuum of care for patients with opioid dependence throughout 
the stages MAT enhances the public health and Recovery from opioid dependence. As a 
stigmatized and medical disenfranchised population with multiple medical, psychological 
and social needs, people who inject drugs and are opioid dependent have difficulty 
accessing services and navigating medical systems of coordinated care. MAT programs that 
offer comprehensive services and medical care options can best contribute to improving the 
health of these individuals thereby enhancing the health of the community.  
OPEN ACCESS Int. J. Environ. Res. Public Health 2011, 8                 
 
 
4103 
Keywords: medication assisted treatment; medical care; infectious diseases; opioid abuse; 
opioid dependence; recovery  
 
1. Introduction 
Drug abuse and dependence is a growing public health problem [1]. Most significant is the global 
increase in opioid abuse and dependence [2]. Opioid abuse and dependence is increasing because of 
the availability of opioids through increased global trafficking of heroin and the widespread increase  
in use of opioid analgesics in the treatment of chronic non  cancer  pain as well as in acute pain 
management [2,3]. Opioids are highly addictive compounds and individuals at high risk who chronically 
use opioids, either as an illicit drug or in the management of pain, can  develop a substance   
use disorder. 
Substance use disorders are defined in the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition [4] as substance abuse and substance dependence. Opioid abuse and dependence are 
chronic, relapsing diseases that can be successfully medically treated. However, they are complex 
physiologic, social, and behavioral disorders that often coexist with psychiatric illness, as well as,  
co-morbid medical infectious diseases such as the HIV, hepatitis virus infection or tuberculosis [5-7]. 
Thus, opioid abuse and dependence are most effectively treated through a set of comprehensive 
medical, social, psychological and rehabilitative services that address all the needs of the   
individual [7,8]. MAT, the use of effective medications in combination with behavioral therapies, is a 
highly effective treatment for opioid abuse and dependence [9]. MAT impacts public health through 
the reduction of opioid use, opioid overdose mortality and transmission of infectious diseases [10].  
2. Opioid Abuse and Dependence and Injection Drug Use 
Exposure to addictive substances is widespread, but vulnerability to substance abuse and dependence 
is behaviorally complex, being a function of biological, psychological and environmental interactions 
and influences [11-14]. Although opioid dependence is characterized by an increased quantity/frequency 
of use, the clinical diagnosis of opioid abuse and dependence is based on maladaptive patterns of opioid 
use, cognitive, behavioral, and physiological symptoms as well as significant consequences related to 
opioid  use [4]. The  characteristic of  tolerance to  opioids based on continued use is particularly 
important in the context of the transition from non-injection opioid use to injection opioid use. 
Drug users transition from non-injecting drug use to injection drug use because injecting drug use is 
considerably more cost effective and provides a more intense drug effect compared to non-injection of 
drugs [15-17]. In addition, studies have shown that the transition to injecting drug use is more likely 
for individuals who consume drugs at higher frequencies. There are also social aspects in the transition 
to injection drug use [18]. Drug users who are homeless or who have been physically abused as well as 
those with social ties to injection drug users are more likely to transition to injecting. The influence of 
social networks on drug use practices is thought to occur both directly and indirectly in the context of 
social comparison and perceived norms that increase risk factors. Opioid injection drug users socially 
connect with other injectors and participate in long term injecting social networks that reinforce Int. J. Environ. Res. Public Health 2011, 8                 
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injecting drug behaviors. These opioid social networks tend to comprise a small number of members 
who develop long term relationships with each other.  
The transition from non-injection drug use to injection drug use presents a formidable public health 
risk for the transmission of both HIV and hepatitis virus infections [19]. The progression to injection 
drug use results in an unhealthy lifestyle with  a poor quality of life, increased morbidity and an 
estimated 12–20 higher risk of mortality [20-22]. The elevated morbidity and mortality results from a 
disenfranchisement from medical care, a behavior that produces a high risk of infections, medical 
complications, and chronic diseases due to unsafe injection practices and sexual risk taking [23-25]  
However, injection drug users are not solely at–risk. Non-injection drug users are at-increased risk 
of death due to drug overdose, and sexually transmitted diseases, including HIV [26,27]. In cities with 
substantial harm reduction and drug treatment programs, the prevalence of HIV infection has been 
shown to be virtually identical for injection drug users and non-injection drug users whether or not 
they are in drug treatment [28]. In this case, sexual HIV risk has become the predominant transmission 
route for HIV infection [29]. Prescription opioid abusers have also been shown to be at risk for HIV 
infection due to an increased number of sexual partners [29]. Prescription opioid abusers have been 
shown to have a high prevalence of psychiatric co-morbidities compared to non-opioid drug users [30]. 
Thus, both injecting and non-injecting drug users exhibit unhealthy lifestyles with the need for substance 
abuse treatment that comprehensively addresses their medical, social, and psychological needs. 
3. Medication Assisted Treatment for Opioid Dependence 
In the United States, the use of pharmacotherapies in combination with counseling and behavior 
therapies to provide a comprehensive therapeutic approach to the treatment of opioid abuse and 
dependence is termed “Medication Assisted Treatment” or MAT. Federally supported research studies 
have developed and shown that the most efficacious treatments  for opioid abuse and dependence 
comprise MAT and include psychosocial counseling, financial, legal, educational services as well as 
wrap around social services [8]. Federal programs catalogue such evidence-based best medical 
practices and promote their implementation in the care and treatment of patients to optimize good 
medical outcomes through the education and training of these medical practices by health care 
providers [16]. Federal programs can also support the piloting of treatment improvement projects to 
develop national implementation strategies. Drug treatment programs that utilize MAT are regulated in 
the US by the federal government in their adherence to treatment standards through accreditation and 
in their record keeping requirements for use of controlled pharmaceuticals [31]. 
Currently, the US Food and Drug Administration (FDA) has approved four medications for the use 
in the treatment of opioid abuse and dependence (see Table 1). Methadone is a Schedule II opioid 
agonist and has demonstrated safety and efficacy in the treatment of heroin abuse and dependence for 
over forty years and more recently in the treatment of prescription opioid abuse and   
dependence [32,33].  However, in the United States methadone is only available  in specialized 
treatment programs, called Opioid Treatment Programs (OTPs),  that are regulated by Center for 
Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration 
(SAMHSA). Primary care providers, therefore, are unable to provide this treatment to patients, but can Int. J. Environ. Res. Public Health 2011, 8                 
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refer patients needing methadone maintenance treatment to an OTP,  if available in their region. 
SAMHSA has recently published a state-by-state profile of OTPs for 2008 that is updated yearly [34]. 
Table 1. Approved pharmacotherapies comprising medication assisted treatment for opioid 
abuse and dependence. 
Methadone—federally regulated through OTP; long-acting opioid receptor agonist for 
pharmacological therapy; can be used in detoxification or in long term (maintenance) 
treatment 
Buprenorphine—office-based opioid treatment or OTPs; federally regulated, long-acting 
opioid receptor partial agonist for pharmacological therapy; can be used in detoxification 
or in long term (maintenance) treatment 
Naltrexone—office-based and substance abuse treatment programs; non-narcotic opioid 
receptor antagonist for relapse prevention without abuse liability or reinforcing effects; 
used after detoxification from opioids to prevent relapse to opioid use 
Vivitrol—extended release naltrexone; non-narcotic opioid receptor antagonist for relapse 
prevention without abuse liability or reinforcing effects; used after detoxification from 
opioids to prevent relapse to opioid use 
Buprenorphine is a Schedule III partial opioid agonist which allows  for qualified and specially 
licensed physicians to treat patients with opioid addiction in a primary care setting. The Division of 
Pharmacologic Therapies at CSAT/SAMHSA provides an online physician and treatment program 
locator at: http://buprenorphine.samhsa.gov/bwns_locator/. In addition, CSAT/SAMHSA provides a 
state-by-state profile of the locations of physicians with waivers to prescribe buprenorphine. 
Buprenorphine treatment of opioid abuse and dependence is reviewed in Treatment Improvement 
Protocol 40 [35]. Buprenorphine has been shown to be safe and effective in the treatment of   
both injection (heroin) opioid use and prescription drug abuse and dependence [36]. Buprenorphine 
has also been developed in a combination form with naloxone to reduce the risk of diversion for illicit 
use.  Models to implement buprenorphine in HIV clinical settings have also been piloted [37].  
The HIV/AIDS Bureau of the Health Resources and Services Administration (HRSA) has developed 
and supported a Special Project of National Significance entitled “The Buprenorphine Initiative:   
An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in   
HIV Primary Care”.  This  five  year initiative, which began in September 2004, comprises  
10 demonstration sites coordinated by a technical assistance/evaluation center that works 
collaboratively to refine planned interventions, addresses state-of-the-art treatment and policy issues 
relating to the use of buprenorphine opioid abuse treatment in HIV primary care settings, and conducts 
local and  multi-site evaluations  and disseminate findings. A special issue of the Journal of the 
Acquired Immune Deficiency Syndrome  (JAIDS)  has been  published  providing a comprehensive 
analysis of the projects [38]. 
Naltrexone is a non-narcotic long-acting, opioid antagonist that blocks opioids binding to the mu 
opioid receptor.  Unlike methadone, there is no negative reinforcement (opioid withdrawal) upon 
discontinuation. Due to naltrexone’s opioid antagonism, patients must abstain from opioids for a 
minimum of seven days prior to starting treatment to avoid the precipitation of opioid withdrawal. The Int. J. Environ. Res. Public Health 2011, 8                 
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effectiveness of naltrexone treatment depends upon patient motivation and social support   
system [39]. Thus, in cultures where there is strong family or social support for the patient in care, oral 
naltrexone has been shown to be effective in the prevention of relapse to heroin use [40]. Because of a 
lack of positive reinforcing effects with naltrexone and low motivation on the part of many patients, as 
well as, poor clinician acceptability, oral naltrexone  is not widely prescribed for the treatment of 
opioid dependence in the United States and thus not seen as a good maintenance treatment medication 
for relapse prevention.  
Vivitrol is an injectable extended-release naltrexone preparation that has recently been approved for 
the treatment of opioid abuse and dependence. Vivitrol addresses the concern of medication adherence 
as a monthly injectable formulation and this extended formulation has been shown to be more effective 
than oral naltrexone [41]. This was also shown in a  recent Phase 3 clinical trial  that  confirmed 
vivitrol’s safety and efficacy in the prevention of relapse to heroin use in a cohort of injection drug 
users. A higher retention in care and higher rates of opioid-free urine screens were observed along with 
a significant reduction in opioid craving compared to placebo. Currently, studies are underway to 
determine the most efficacious service model(s) for the use of vivitrol in the treatment of relapse 
prevention to heroin use.  
4. Health Service Models for Medication Assisted Treatment (MAT) 
Health service programs deliver MAT in a regulatory environment where both the federal 
government and state/local government provide a regulatory framework for the access to and delivery 
of medications that are controlled by international convention [42]. In the United States, state and local 
regulations can enhance the federal regulations, but they cannot replace the federal regulations. The 
MAT federal regulations can be found in the Code of Federal Regulations [43] and establish 
procedures to determine if a health practitioner is qualified to dispense methadone in the treatment of 
opioid abuse and dependence in opioid treatment programs, as well as, the quantity of methadone that 
can be provided for unsupervised use by patients. Thus, the federal regulations address the balance 
needed in the use of controlled medications for treatment versus the restrictions to limit diversion of 
the addictive medication.  
The MAT federal regulations regulate health service models  restricting the dispensing of 
methadone to OTPs, but allows buprenorphine to be provided in an office base setting by registered 
and trained physicians. There are no prescribing restrictions for naltrexone and vivitrol, since these 
medications are not scheduled narcotics with federal controls. Federal regulations that allow the use of 
MAT in office based settings enhance access to MAT by providing additional venues where patients 
access pharmacotherapy for opioid dependence. The differing regulations for the use of methadone and 
buprenorphine in the treatment of opioid dependence result in differing treatment locations and 
treatment environments. There are a limited number of OTPs in the United States that dispense both 
methadone and buprenorphine,  while there are only three OTPs that dispense exclusively 
buprenorphine. The highly regulated OTP where methadone is predominately used to treat opioid 
dependence are considered ‘strict” treatment environments with required daily appearance for 
medication and mandated urine tests for illicit drug use [43]. Office based opioid treatment (OBOT), 
on the other hand, was developed, in part, to reduce the stigma and discrimination associated with the Int. J. Environ. Res. Public Health 2011, 8                 
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treatment of opioid dependence. Providing pharmacotherapies for opioid dependence to patients in a 
medical office setting is less structured than an OTP and based on the 2005 evaluation of OBOT has 
resulted in the following: approximately one-third of patients new to substance abuse  treatment; 
roughly sixty percent new to pharmacotherapy; less than ten percent switching from methadone to 
buprenorphine treatment ; and a majority of patient noted to be receiving treatment for dependence to 
prescription drug (non-heroin) opioids [44].  
The treatment environment and range of services provided either in OTPs or in OBOT are 
important in maintaining patients in care and treatment. Treatment programs that are patient  
centered, provide a supportive environment and meet the needs of  the patient, regardless of the 
pharmacotherapy used in treatment, result in patients remaining in treatment for longer periods of time. 
Patients who remain in treatment have better treatment outcomes due to adherence compliance and 
persistence [45-47]. These are important characteristics in designing model MAT programs to ensure 
good clinical and public health outcomes. Barrier free access to MAT is important to obtain maximal 
public health impact and reach all opioid abusing individuals seeking treatment [48]. Thus,  MAT 
programs providing comprehensive services as part of the continuum of care (see Table 2) in an 
enabling environment result in quality and effective substance abuse treatment services that promote 
individual well-being and improved community health. 
Table 2.  Elements of the continuum of care in the treatment of opioid abuse and 
dependence [49]. 
(1) Prevention of drug initiation 
Interventions to reduce the risk of drug and alcohol initiation of use and abuse  
Interventions to reduce the risk of sexually transmitted diseases, including HIV  
Individual targeted interventions through the life span 
Family targeted interventions 
Community interventions 
(2) Identification of substance use conditions 
Screening for drug use-patient self-report, prescription monitoring programs, collaterals 
Case finding 
Assessment and diagnosis 
(3) Initiation and engagement in drug treatment 
Brief intervention 
Promoting engagement, case management/care navigators  
Detoxification/Withdrawal management 
Assessment of social, co-morbid medical conditions and co-occurring disorders 
Pharmacotherapy 
(4) Long term treatment of substance use illness 
Psychosocial 
Treatment of co-morbid medical conditions and co-occurring disorders 
Promote social stability through addressing legal, social, educational, financial issues  
(5) Primary care and post treatment management of patient 
Recovery 
Relapse prevention 
Rehabilitation  
Medical home Int. J. Environ. Res. Public Health 2011, 8                 
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Medical treatment programs that provide  MAT as part of a  comprehensive  set of  services  can 
interface substance abuse treatment services with primary medical care, infectious disease services, 
and social/rehabilitation services. That interface can be comprehensive through the integration of 
substance abuse treatment services, primary medical care, infectious  disease prevention, care and 
treatment and social/rehabilitation services. An integrated care and treatment model where MAT 
services are provided within primary care uses a single medical record minimizes the stigma and 
discrimination associated with drug  treatment services while improving overall health outcomes, 
particularly for patients with multiple health issues, in a cost-effective manner [50]. 
For OTPs,  methadone  dispensing, primary medical care, infectious disease services,  and 
social/rehabilitation services are integrated on-site in the structured environment where methadone is 
dispensed [51,52]. Based on patient needs, various types of health services can be integrated into OTP 
MAT services including primary care, mental health, and infectious diseases. Some of the limiting 
factors for the integration of services are the organizational structure of the OTP, incorporating new 
procedures in primary care and cost of services [52,53].  
4.1. Integrated Models of MAT 
Buprenorphine, an opioid agonist medication, is approved and regulated in the United States for 
OBOT.  As noted earlier, an office based setting provides enhanced access to  buprenorphine in a 
primary care environment, where health services can be integrated [54]. Multiple models have been 
piloted for the integration of MAT using buprenorphine within HIV primary care [55]. These include 
an on-site combination of addiction treatment/HIV specialist treatment; a HIV primary care physician 
prescribing buprenorphine; a non-physician health care provider integrating medical care and 
substance abuse treatment services using buprenorphine; and a community outreach model where 
buprenorphine is provided along with medical services in a mobile van [55]. These pilot projects have 
uncovered barriers to integrating MAT using buprenorphine within HIV primary care that are both 
financial and regulatory. Regulatory challenges include licensing and training restrictions imposed by 
the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug 
treatment records [56]. A recent study has shown that in a primary care setting using buprenorphine, 
prescription opioid dependent patients showed better clinical outcomes compared to patients who were 
dependent on heroin [57].  
Naltrexone is a non-narcotic and therefore non-controlled medication for the treatment of opioid 
abuse as well as alcohol abuse. Naltrexone integrated with mental health services, particularly 
psychosocial treatment has been shown to be an effective maintenance treatment for reducing heroin 
use after detoxification [58]. In addition, using clonidine and naltrexone together can be successfully 
integrated into a primary care setting [59]. In this study retention in care and successful detoxification 
from opioid abuse was observed with MAT using either naltrexone or buprenorphine. In other care 
settings, treatment of alcohol use disorders using naltrexone has been successfully integrated into the 
treatment of patients who have tuberculosis [60]. Current efforts are determining the optimum 
conditions to integrate vivitrol (extended release naltrexone) into HIV primary care programs. 
Additionally, how to integrate vivitrol into an OTP setting and in primary medical care as a relapse Int. J. Environ. Res. Public Health 2011, 8                 
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prevention intervention for patients following buprenorphine detoxification, respectively is currently 
moving forward[61].  
4.2. Coordinated Care Models of MAT 
Medical service programs can connect substance abuse treatment services with primary medical 
care and social/rehabilitation services in a non-integrated but coordinated fashion. In these programs, 
MAT services work with primary medical care and social/rehabilitation services to provide good 
patient outcomes and enhance community health. MAT, health services and social/rehabilitation 
services can be separately managed with a different network of health care providers but co-located to 
allow convenient utilization of primary care, MAT and other services. An additional coordinated 
approach provides primary care, MAT and other services at distinct locations through differing 
network of health care providers. A recent study has shown twice as many patients retained in MAT 
when the MAT services were provided at single location compared to referral of MAT to a distant 
location [62]. However, coordinated programs can be effective when case managers, peer facilitators, 
or  care navigators  promote or support service utilization at the various locations. For example a 
referral system was modeled with linkage to treatment services for substance use, mental health and 
social services for HIV+ patients receiving HIV primary care [63]. Patients in this model were referred 
to MAT either at an OTP or in an office based setting using buprenorphine. An alternative model 
provided highly stable OTP patients with a 28 day supply of methadone doses and required a monthly 
check-in. Successful patients were noted to have increased family and social activities and failed 
patients were provided stepped treatment intensification [64]. 
A unique Induction/Maintenance model for buprenorphine is the model where a substance abuse 
treatment specialist provides the initial treatment (induction) with buprenorphine until the patient is 
stabilized. Then the patient is transferred/referred to a primary care physician who then provides 
maintenance buprenorphine treatment and medical primary care. This so called ‘wheel and spoke 
model’ allows for substance abuse treatment specialists to manage the more difficult portion of 
buprenorphine treatment (early treatment –or induction phase) while the primary care medical program 
manages the long term maintenance phase of buprenorphine treatment [65]. This model is important in 
the United States since the Drug Addiction Treatment Act of 2000 limits the number of patients a 
qualified buprenorphine treatment provider can manage in their practice [66]. This model has been 
adapted to HIV+ patients where the buprenorphine induction is performed by the substance abuse 
treatment specialist and then the patient is transferred/ referred to the HIV primary care physician [67]. 
Coordinated MAT for patients seeking relapse prevention interventions after detoxification for 
opioid can be provided by naltrexone or the recently approved longer acting, extended release vivitrol. 
As noted earlier, naltrexone it is not widely prescribed for the treatment of opioid dependence in the 
United States, but is provided as an office based treatment for opioid dependence after detoxification. 
In addition, studies have shown that the extended release formulations are effective in reducing opioid 
use and retaining patients in care after detoxification [68,69]. Int. J. Environ. Res. Public Health 2011, 8                 
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5. Public Health and Recovery from Opioid Dependence  
The stages or phase of MAT are shown in Table 3. The patient travels through these three stages of 
treatment, sometimes linearly and sometimes oscillating between phases. The ultimate goal of entering 
MAT is a good clinical outcome which includes the recovery from opioid abuse and dependence and 
social reintegration back into society. The individual in recovery is a functioning member of the 
community and contributes to the public health of the community. Thus, the foundation that MAT is 
structured upon obtaining recovery from opioid abuse and dependence [70].  
Table 3. Stages or phases of MAT. 
•  Induction 
o  Medication is chosen based on clinical and patient circumstances—addiction history, severity 
of withdrawal symptoms, available social support and overdose diagnostic severity 
o  MAT initiation where initial dosing of medication is observed and dosing titration is performed 
by a clinician 
o  Dosing and dose titration is based on expression and control of withdrawal symptoms and is a 
critical period in terms of risk of opioid overdose in treatment 
o  Procedures for patient observation during and after dose titration are incorporated into the clinic 
setting 
o  Induction can last 7–10 days with the goal of obtaining a therapeutic dose of opioid medication 
•  Stabilization 
o  Stabilization phase occurs when the patient no longer exhibits drug seeking behavior or craving 
o  The correct dosage of medication is critical (overdosing versus underdosing) as well as 
successful participation of the patient in behavioral therapies and rehabilitation services 
o  MAT provider determines stabilization based on patient symptoms, not on opioid free urine 
samples  
o  Individual patient health (e.g., pregnancy, liver disease, etc.), other medical treatments 
including HAART and TB treatments, and other drug use or alcohol consumption affects 
stabilization and is addressed 
o  Individual risk assessments are performed and risk reduction interventions implemented to 
reduce the risk of co-infections and co-morbidities 
•  Maintenance 
o  Maintenance pharmacotherapy occurs when the patient is responding optimally to medication 
treatment and routine dose adjustments are not needed.  
o  Patients at this stage have stopped using illicit opioid and resumed productive lifestyles away 
from the local drug culture.  
o  It is also at this stage that patients should have minimal or normal medical needs and can move 
away from intensive drug treatment settings and receive their medications in a primary 
care/community setting.  
o  Typically take-home medication is allowed for patients 
o  If maintenance phase cannot be reached, other drug dependence treatment approaches should be 
explored to complement MAT Int. J. Environ. Res. Public Health 2011, 8                 
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The recovery process is the way in which a person actively manages their substance use disorder 
with efforts to reclaim a full and meaningful life in the community. Recovery is a personal process of 
growth and change which embraces hope, autonomy and the elements that results in re-establishing a 
satisfying and productive life. MAT becomes a recovery oriented system of care when its services and 
integration with other medical, social and rehabilitative services support the individual’s and family’s 
long term efforts to reclaim full and meaningful lives in the community. Important in recovery is the 
provision of comprehensive services in the context of MAT but also a supportive, enabling 
environment that fosters individual responsibility over one’s health and empowerment to change to a 
healthy lifestyle [71]. Promoting the change to a healthy lifestyle is the development of an individual 
risk reduction program to reduce the risk of newly acquired sexually transmitted infection and 
complicating co-morbidities.  
MAT as a recovery orientated system of care has four phases, as shown in Table 4, along with a  
set of recovery oriented strategies and services [72]. An important consideration in phase four,   
long term sustained recovery, is the personal  and clinical  decision to continue with medical 
maintenance of pharmacotherapy or to taper the medication. In either case, the home or living 
environment is critical to the prevention of relapse to opioid use. To prevent relapse of opioid use the 
dependent needs a drug free environment. While significant gains have been made through national 
prevention programs such as “Drug Free Communities”, it remains a Herculean task to keep a 
community entirely free of illicit drug use. Thus, for long term recovery the home or living 
environment is where recovery is nucleated [73]. Local peer recovery programs and recovery oriented 
systems of care that link to or provide individualized, quality long term care that supports recovery 
from a diagnosis of opioid dependence are critical [74]. These settings provide a network of people to 
support abstinence and a low risk environment to support recovery. Receiving abstinence support, 
guidance and information from a recovery home that is committed to long term sobriety reduces the 
risk of relapse to illicit opioid use. These homes need to be considered as a fundamental component in 
the development and maintenance of the public health of communities. 
Table 4. Phases and goals of MAT recovery oriented systems of care. 
•  Recovery initiation and stabilization 
o  Major goal—introduce and educate the patient on pharmacotherapy; eliminate use of illicit 
opioid use as well as other drugs of abuse for at least twenty-four hours 
  Educate the patient about the risk and benefits of pharmacotherapy 
  Provide a choice of alternate/supplemental therapeutic approaches 
  Identify patient’s treatment needs and engage  
  Monitor sedative and side effects of medication  
  Asses safety and adequacy of each dose after administration 
  Discourage self-medication of withdrawal symptoms 
  Assess and initially address medical, social, legal, family and other problems 
including risk reduction strategies 
  Develop initial coping and craving strategies Int. J. Environ. Res. Public Health 2011, 8                 
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Table 4. Cont. 
•  Early recovery and rehabilitation 
o  Major goal—empower individuals to cope with life problems, medical needs co-occurring 
disorders vocational and educational needs, family problems, legal issues and develop long 
term goals for education, employment and family reconciliation 
  Insure medication dose promotes daily comfort 
  Link patient to family and peer-recovery support 
  Develop recovery plan 
  Assess and address personal strengths and needs 
•  Recovery maintenance 
o  Major goal—patient assumes primary responsibility for their life 
  Patient receives needed integrated services 
  Patient is active in community recovery support programs 
  Patient receives take home medication from an OTP 
  Decision on medical maintenance or tapering of pharmacotherapy 
•  Long-term sustained recovery 
o  Major goal—continued primary responsibility for life 
  Taper of pharmacotherapy—quarterly or biannual check-up from substance abuse 
treatment program 
  Continuing pharmacotherapy—continued regular check-up with substance abuse 
treatment provider 
  Continued engagement with peer-based recovery support program 
  Patient becomes a peer recovery support for other patients 
Conclusions 
The use of pharmacotherapies in the treatment of opioid dependence in the form of medication 
assisted treatment is an important tool to enhance public health. Integrating  the substance abuse 
treatment services that comprise medication assisted treatment with other medical,  social  and 
community services provides the best platform for promoting recovery from opioid dependence.  
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